general overview of asco gi 2018 -...

General Overview of ASCO GI 2018

Alberto Zaniboni Oncologia Medica

Fondazione Poliambulanza - Brescia

Le mie disclosures

Research grants: Roche, Novartis, Pfizer, Astra Zeneca, Janssen, Boheringer

Advisory boards / Speaker Bureau: Amgen, Merk Serono, Bayer, Servier, BMS, Lilly, Sanofi

ASCO GI 2018

Esophageal and GEJ Adenocarcinoma: Current Outcomes + Future Directions

Presented By David Ilson at 2018 Gastrointestinal Cancers Symposium

FLOT4 Study Design

Presented By Jaffer Ajani at 2018 Gastrointestinal Cancers Symposium

Since 2006: 5-Y OS nearly doubled compared with surgery alone

Presented By Salah-Eddin Al-Batran at 2018 Gastrointestinal Cancers Symposium

Presented By Salah-Eddin Al-Batran at 2018 Gastrointestinal Cancers Symposium

ECF or any of its modifications should be abandoned


FLOT should be reserved for an occasional patient


RAINFALL: A randomized, double-blind, placebo-controlled phase 3 study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in

patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.

Presented By Charles Fuchs at 2018 Gastrointestinal Cancers Symposium

RAINFALL Trial Design:

Presented By Charles Fuchs at 2018 Gastrointestinal Cancers Symposium

Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer – final results

of a randomized phase II AIO trial

Presented By Florian Lordick at 2018 Gastrointestinal Cancers Symposium

Catumaxomab (CATU)

Presented By Florian Lordick at 2018 Gastrointestinal Cancers Symposium

ASCO GI 2018

Duration of Adjuvant Therapy for Colon Cancer: Is 3 Months Enough? The U.S. Perspective

Presented By Jeffrey Meyerhardt at 2018 Gastrointestinal Cancers Symposium

Duration of Adjuvant Therapy for Colon Cancer – is 3 Months Enough? The European Perspective

Presented By Timothy Iveson at 2018 Gastrointestinal Cancers Symposium

6 months after ASCO: How are IDEA Results Being Interpreted/Incorporated


ARS 1: 34-year-old male with well differentiated, T3 colon cancer with 1 of 15 positive lymph nodes. What would you recommend for adjuvant therapy?


Colorectal Cancer With Peritoneal Metastasis: A Regional Disease Requiring Regional Therapy CON

Presented By Garrett Nash at 2018 Gastrointestinal Cancers Symposium

Role of (Neo) Adjuvant Chemotherapy for Rectal Cancer The European approach

Presented By Cornelis Van De Velde at 2018 Gastrointestinal Cancers Symposium

Nivolumab in Patients With DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer: Long-Term Survival According to Prior Line of Treatment

From CheckMate-142

Presented By Michael Overman at 2018 Gastrointestinal Cancers Symposium

Nivolumab + Ipilimumab Combination in Patients With DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer: First Report of the Full

Cohort From CheckMate-142

Presented By Thierry Andre at 2018 Gastrointestinal Cancers Symposium

Presented By Johanna Bendell at 2018 Gastrointestinal Cancers Symposium

Presented By Kohei Shitara at 2018 Gastrointestinal Cancers Symposium

ASCO GI 2018

Presented By Juan Valle at 2018 Gastrointestinal Cancers Symposium

Stereotactic Body Radiotherapy (SBRT); What Role Does Focal Radiotherapy Play for Hepatocellular Carcinoma

Presented By Jinsil Seong at 2018 Gastrointestinal Cancers Symposium

Presented By Ann-Lii Cheng at 2018 Gastrointestinal Cancers Symposium

Conclusions (2018 perspective of systemic tx for HCC)

Presented By Ann-Lii Cheng at 2018 Gastrointestinal Cancers Symposium

Presented By Jordi Bruix at 2018 Gastrointestinal Cancers Symposium

Presented By Masatoshi Kudo at 2018 Gastrointestinal Cancers Symposium

KEYNOTE-224: Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib

Presented By Andrew Zhu at 2018 Gastrointestinal Cancers Symposium

Cabozantinib versus placebo in patients with advanced hepatocellular carcinoma who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial

Presented By Ghassan Abou-Alfa at 2018 Gastrointestinal Cancers Symposium

Presented By Ramesh Ramanathan at 2018 Gastrointestinal Cancers Symposium

ABSTRACT 204

Presented By Pascal Hammel at 2018 Gastrointestinal Cancers Symposium

general overview of asco gi 2018 -...

Documents